Irish healthcare services group Uniphar has reported revenue of €3.07bn for the year to December 31, 2025, up 11 per cent on the previous year, according to Irish Independent.

The Dublin-headquartered business recorded gross profit rising 7 per cent to €457.7m whilst earnings before interest, tax, depreciation and amortisation increased to €130.9m.

On an organic basis, which strips out the impact of acquisitions and disposals, gross profit grew 8.9 per cent. Adjusted earnings per share climbed 21 per cent to 24.8 cent, helped by lower finance costs and a €35m share buyback completed during the year. In total, 13.4 million shares were repurchased.

Pre-tax profit, excluding exceptional items, rose 17.4 per cent to €71.8m. However, operating profit fell 6.2 per cent to €76.9m, whilst gross profit margin eased to 14.9 per cent from 15.4 per cent a year earlier.

Uniphar operates across three main areas: pharma, medtech and supply chain and retail. The pharma section delivered organic gross profit growth of 15.5 per cent, driven by demand for global sourcing and clinical trial supply services. Medtech reported 10.5 per cent organic growth, supported by expansion in core markets and the rollout of new suppliers. Supply chain and retail recorded 4.2 per cent organic growth, with its retail pharmacy network expanding by 37 stores to 482 pharmacies.

Net bank debt increased to €171.1m from €147.7m. The group extended the maturity of its main revolving credit facility to August 2029 and put in place a new €150m five-year term loan. Free cash flow conversion was 99.1 per cent for the year.

Discover how Uniphar achieved record revenue and earnings growth in the complete article.